Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment

Shu Zhang, Xiaojuan Zhang, Huan Gao, Xiaoqin Zhang, Lidan Sun, Yueyan Huang, Jie Zhang, Baoyue DingPharmaceutics 2024 · DOI

TL;DR

Cell membrane-coated nanoparticles (CMC@NPs) are emerging as a powerful strategy to overcome the limitations of traditional nanoparticle drug delivery for cancer treatment. By cloaking nanoparticles with cell membranes, researchers are achieving enhanced tumor targeting, improved biocompatibility, and reduced immune system clearance, paving the way for more effective and personalized cancer therapies.

What Problem Does This Paper Address?

Despite the promise of nanoparticle-based drug delivery systems (DDSs) for cancer treatment, significant challenges remain. These include inadequate targeting of cancer cells, leading to off-target side effects, and limited biocompatibility, which can trigger immune responses and rapid clearance from the body. Traditional methods like PEGylation offer some improvement but can lead to accelerated blood clearance with repeated use. This review addresses the need for DDSs that can overcome these hurdles by mimicking biological systems, specifically by leveraging the inherent properties of cell membranes.

Methods

This review focuses on cell membrane-coated nanoparticles (CMC@NPs), which are created by using cell membranes as a natural outer shell for synthetic nanoparticles. The preparation methods discussed primarily involve top-down approaches:

  • Co-extrusion: Extruding cell membrane vesicles and nanoparticles through polycarbonate membranes to fuse them.
  • Sonication: Using ultrasonic waves to fuse membrane vesicles and nanoparticles.
  • Microfluidic Electroporation: Employing microfluidic chips to create pores in membranes and facilitate NP integration.

The review categorizes CMC@NPs based on the source of the cell membrane, including red blood cells (RBCs), platelets (PLTs), white blood cells (WBCs), stem cells (SCs), cancer cells (CCs), and hybrid combinations. It then details their applications in various cancer treatment modalities.

Datasets

Not discussed in the paper. This is a review article summarizing existing research.

Key Insights and Ideas

  • Biomimicry is Key: The core idea is to "learn from nature." By coating synthetic nanoparticles with cell membranes, we can imbue them with the natural functionalities of those cells, such as immune evasion and specific targeting.
  • "Self" Identity: Cell membranes act as a "disguise," making the nanoparticles appear as "self" to the immune system, thus avoiding rapid clearance by the reticuloendothelial system and prolonging circulation time.
  • Targeted Delivery: Different cell membranes possess unique surface proteins and receptors that can be exploited for specific targeting. For example, cancer cell membranes can facilitate homotypic binding to cancer cells.
  • Multifunctionality: Hybrid membranes, created by fusing membranes from different cell types, offer the potential to combine multiple desirable properties (e.g., long circulation from RBCs and tumor targeting from cancer cells).
  • Therapeutic Versatility: CMC@NPs are not limited to chemotherapy; they show promise in gene therapy, immunotherapy, photodynamic therapy, photothermal therapy, and combination therapies.

Key Results

This review highlights numerous studies demonstrating the efficacy of CMC@NPs. While specific quantitative results vary by study and application, the overarching findings include:

  • Enhanced Circulation Time: RBCm@NPs, for instance, have shown significantly longer circulation half-lives compared to PEG-coated NPs.
  • Improved Tumor Accumulation: CMC@NPs, particularly those with specific targeting moieties, demonstrate increased accumulation at tumor sites.
  • Reduced Immunogenicity: The cell membrane coating effectively shields nanoparticles from immune detection, leading to reduced phagocytosis.
  • Therapeutic Efficacy: Various CMC@NPs have shown significant tumor growth inhibition, improved therapeutic outcomes in preclinical models, and enhanced immune responses against tumors. For example, ICUR-DOX@RBC demonstrated prolonged blood circulation and significantly enhanced tumor growth inhibition.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Targeting Specificity: While many CMC@NPs show improved targeting, achieving precise specificity remains a challenge, especially with certain cell types like RBCm@NPs.
  • Heterogeneity: WBCm@NPs, for example, exhibit high heterogeneity, which can impact their performance.
  • Safety Concerns: CCm@NPs, while effective, raise safety concerns due to potential oncogenic risks.
  • Manufacturing Challenges:
    • Cell Scarcity and Cost: Obtaining certain cell types for membrane harvesting can be scarce and costly.
  • Purity: Thorough removal of intracellular contents and genetic material is crucial, especially for cancer cell membranes, to avoid carcinogenic risks.
  • Stability: Maintaining the integrity of surface proteins requires low-temperature preparation and storage, posing challenges for long-term preservation.
  • Upscaling: Most preparation methods are currently confined to lab-scale experiments, requiring optimization for industrial production due to laboriousness, low efficiency, and inconsistent results.
  • Clinical Translation: The transition from laboratory settings to clinical practice faces hurdles related to operational complexity, time efficiency, cost, and the need for standardized protocols.
  • Future Directions:
    • Developing more efficient and easily adaptable coating techniques.
  • Exploring personalized healthcare approaches using self-derived cell membranes.
  • Investigating hybrid membranes and advances in biological membrane modification.
  • Leveraging extracellular vesicles (EVs) like exosomes and microvesicles for their cargo transport capabilities.
  • Streamlining and standardizing preparation processes to reduce cost and time.

Summary updated

Abstract

Nanoparticle-based drug delivery systems hold promise for cancer treatment by enhancing the solubility and stability of anti-tumor drugs. Nonetheless, the challenges of inadequate targeting and limited biocompatibility persist. In recent years, cell membrane nano-biomimetic drug delivery systems have emerged as a focal point of research and development, due to their exceptional traits, including precise targeting, low toxicity, and good biocompatibility. This review outlines the categorization and advantages of cell membrane bionic nano-delivery systems, provides an introduction to preparation methods, and assesses their applications in cancer treatment, including chemotherapy, gene therapy, immunotherapy, photodynamic therapy, photothermal therapy, and combination therapy. Notably, the review delves into the challenges in the application of various cell membrane bionic nano-delivery systems and identifies opportunities for future advancement. Embracing cell membrane-coated biomimetic nanoparticles presents a novel and unparalleled avenue for personalized tumor therapy.
BibTeX
@inproceedings{zhang2024cell,
  author = {Shu Zhang and Xiaojuan Zhang and Huan Gao and Xiaoqin Zhang and Lidan Sun and Yueyan Huang and Jie Zhang and Baoyue Ding},
  title = {{Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment}},
  booktitle = {Pharmaceutics},
  year = {2024},
  doi = {10.3390/pharmaceutics16040531},
}
Figure